Just reported
From Stryker's results release of 2026년 10월 29일; its quarterly report has since been filed.
Actual
US$6.52B
+7.6% y/y
-1.0% q/q
Guided
—
No guide given
Actual
US$1.96
-12% y/y
-41% q/q
Guided
—
No guide given
Actual
US$1.03B
-8.9% y/y
-38% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →매출 비중은 nine months ended 2026-09-30 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
Surgical instruments and navigation systems
Powered surgical tools and navigation equipment that help surgeons carry out procedures.
Endoscopy and communications equipment
Cameras and related equipment that let clinicians view inside the body, alongside systems that connect operating-room equipment.
Patient and emergency-care equipment
Hospital beds, patient-handling equipment, emergency monitors and defibrillators, intensive-care disposables, and clinician communication systems.
Minimally invasive vascular devices
Catheters and other devices used in minimally invasive treatment of stroke and venous blood clots.
Brain and cranial surgery products
Products for brain and open-skull surgery, including synthetic bone grafts and products used to treat spinal bone conditions.
Joint and trauma implants and robotic surgery systems
Hip, knee, shoulder, ankle and trauma implants, plus robotic systems and surgical tools used in these operations.
Stryker makes equipment used during operations and in hospital wards, including cameras, surgical instruments, beds, emergency devices and systems that help hospital staff communicate. It also makes minimally invasive devices to treat strokes and blood clots, plus implants and robotic systems used in joint replacement and trauma surgery. It sells mainly to doctors, hospitals and other healthcare facilities, both directly and through distributors.
Stryker Corp.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
US$309.64-0.9%11월 13일 종가
2026년 9월 30일까지의 수치 (2026년 10월 30일 제출 10-Q 기준)
Stryker sells operating-room and hospital-care equipment and minimally invasive stroke and clot-treatment devices to hospitals and clinicians, alongside implants and robots for joint surgery.
The themes Stryker is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$131.6BA+
EWEdwards Lifesciences CorporationUS$61.6BA+
GEHCGE Healthcare Technologies Inc.US$37.5BA
GKOSGlaukos CorpUS$14.5BA
PENPenumbra, IncUS$12.7BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now AEWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now AGEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now AGrade A+
주가 아래 띠는 각 날짜의 등급으로, 그 시점까지 공개된 자료만으로 산출했습니다.
Stryker Corp.의 등급 이력 41개 분기 중 2개를 표시하고 있습니다. 나머지 39개는 2016년 10월까지 거슬러 올라갑니다.
